|
TCF12 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.20079999779799E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.383499999707E-07 |
| Normal-vs-Stage2 |
1.89200999999306E-05 |
| Normal-vs-Stage3 |
2.84179999976431E-07 |
| Normal-vs-Stage4 |
2.17209999986423E-07 |
| Stage1-vs-Stage2 |
4.573400E-01 |
| Stage1-vs-Stage3 |
1.505220E-01 |
| Stage1-vs-Stage4 |
2.000800E-01 |
| Stage2-vs-Stage3 |
7.630400E-01 |
| Stage2-vs-Stage4 |
6.728800E-01 |
| Stage3-vs-Stage4 |
8.956400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.71309999811243E-08 |
| Normal-vs-AfricanAmerican |
4.743900E-02 |
| Normal-vs-Asian |
3.578999999998E-05 |
| Caucasian-vs-AfricanAmerican |
1.370620E-01 |
| Caucasian-vs-Asian |
9.492600E-01 |
| AfricanAmerican-vs-Asian |
1.775050E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.86879999942403E-08 |
| Normal-vs-Female |
1.0839999997625E-07 |
| Male-vs-Female |
6.419400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.11199999999856E-06 |
| Normal-vs-Age(41-60Yrs) |
1.08619999994453E-07 |
| Normal-vs-Age(61-80Yrs) |
2.31160000030428E-07 |
| Normal-vs-Age(81-100Yrs) |
1.468490E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.676400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.453200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.290600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.831200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.560200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.232600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.683220E-01 |
| Classical-VS-Follicular |
1.230010E-02 |
| Classical-VS-Other |
2.278600E-01 |
| Classical-VS-Normal |
3.65049999995204E-06 |
| Tall-VS-Follicular |
8.174400E-01 |
| Tall-VS-Other |
6.298600E-01 |
| Tall-VS-Normal |
6.13529999999862E-05 |
| Follicular-VS-Other |
7.418400E-01 |
| Follicular-VS-Normal |
1.21769999972265E-07 |
| Other-VS-Normal |
5.177800E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.21080000470286E-08 |
| Normal-vs-N1 |
3.1269000000389E-07 |
| N0-vs-N1 |
5.092400E-01 |
|
|
